Jordyn Sava is an editor for Targeted Oncology.
According to topline findings of the phase 3 KEYNOTE-966 trial, pembrolizumab in combination with gemcitabine and cisplatin led to an improvement in overall survival for patients with biliary tract cancer.
In an interview with Targeted Oncology, Carolyn Owen, MD, discussed findings from the GLOW study of elderly/unfit patients with chronic lymphocytic leukemia that were presented at SOHO 2022.
Following positive data from the phase 1 ReSPECT-GBM trial, the first patient has been dosed with rhenium (186Re) obisbemeda in the phase 2 portion.
In an interview with Targeted Oncology, Thomas Flaig, MD, further discussed the updates to the 2022 NCCN guidelines for patients with bladder cancer and explained how the field has evolved over the past few years.
In an interview with Targeted Oncology, Melanie Goldfarb, MD, MSc, FACS, FACE, highlighted the importance of long-term survivorship care and the quality-of-life aspects of patients with thyroid cancer.
An investigational new drug application for IMPT-314 has been cleared by the FDA. A phase 1/2 trial investigating the agent will be initiated in early 2023.
In an interview with Targeted Oncology, Tanios Bekaii-Saab, MD, FACP, discussed the methods and design of the MOUNTAINEER-03 trial and its role following the positive data observed from MOUNTAINEER.
After the FDA cleared an investigational new drug application for mocravimod in April 2022, the first patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant have been enrolled in a phase 2b/3 study of the agent.
Patients with advanced hepatocellular carcinoma who were treated with lenvatinib following progression on immunotherapy had a median overall survival of 12.8 months and progression-free survival of 3.7 months.
Phase 2 study shows ponatinib and blinatumomab to represent a promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.
LNS8801 has proven to be safe, well-tolerated, and demonstrated clinical benefit in patients with advanced cancers. Now, the FDA has granted the agent orphan drug designation for metastatic cutaneous melanoma.
A substudy of the TIGeR-PaC trial showed that treatment with RenovoTAMP may increase local gemcitabine delivery and decrease the debilitating adverse events associated with intravenous administration in pancreatic cancer.
Teon Therapeutics has entered into a clinical trial collaboration with Merck to assess TT-816 and pembrolizumab in a phase 1/2 study.
Preliminary data from the KYM901 trial of CMG901 revealed promising safety findings for patients with solid tumors. Full data will be presented at the upcoming 2023 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology.
Updated guidelines recommend olutasidenib as a targeted therapy for patients with relapsed/refractory acute myeloid leukemia with an IDH1 mutation.
Based on the acceptance of its investigational new drug application by the FDA, the safety and tolerability of HT-001 will be evaluated in the phase 2a CLEER of patients with rash and skin disorders associated with EGFR inhibitor therapy.
In an interview with Targeted Oncology, Gayathri Ravi, MD, further discussed findings from a presentation at ASH 2022, and the role of minimal residual disease testing in multiple myeloma.
Following clearance by the FDA and AEMPS, the phase 2b VIRAGE trial of VCN-01 plus gemcitabine and nab-paclitaxel dosed its first patient with pancreatic ductal adenocarcinoma.
BXQ-350 in combination with modified FOLFOX7 and bevacizumab will be evaluated in a phase 1b/2 study of metastatic colorectal carcinoma.
In an interview with Targeted Oncology, Jennifer R. Brown, MD, PhD, discussed the findings from the ALPINE study and the effectiveness of zanubrutinib when used for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
In an interview with Targeted Oncology, Ben Derman, MD, discussed data from an ongoing clinical trial evaluating MRD-guided discontinuation of maintenance therapy in patients with multiple myeloma.
With the FDA clearing an investigational new drug application for HBM1020, the antibody can begin to be evaluated in clinical trials of patients with solid tumors.
In an interview with Targeted Oncology, Yazan Samhouri, MD, discussed new agents, clinical trials, and developments creating change in diffuse large B-cell lymphoma, as well as the key takeaways from ASH 2022.
Findings from the phase 2 ROCKET trial showed a benefit in progression-free survival, overall survival, and overall response rate in patients with colorectal cancer treated with RRx-001 plus irinotecan.
JBI-802, which is being evaluated in a phase 1/2 trial, received an orphan drug designation from the FDA for the treatment of patients with small cell lung cancer and acute myeloid leukemia.
In a cohort of 7 patients with ER+ breast cancer, treatment with zotatifin in combination with fulvestrant and abemaciclib led to 2 partial responses and and additional patient with stable disease continuing beyond 24 weeks.
In an interview with Targeted Oncology, Srdan Verstovsek, MD, discussed the potential use of momelotinib as a treatment for patients with myelofibrosis if approved by the FDA in June 2023.
Based on the positive interim safety data from a phase 1 trial of STRO-002, the phase 2/3 REFRaME study will be initiated to further evaluate the agent in patients with advanced ovarian cancer.
Azeliragon has been granted an orphan drug designation by the FDA for patients with glioblastoma after previous trials demonstrated the agent to be well-tolerated in Alzheimer’s disease.
Starting with the PRESERVE 1 trial of patients with metastatic colorectal cancer, 5 pivotal trials evaluating trilaciclib will announce results in 2023.